March 10 (Reuters) - Trevi Therapeutics Inc TRVI.O:
TREVI THERAPEUTICS INC: HADUVIO MET PRIMARY ENDPOINT
TREVI THERAPEUTICS: ANNOUNCE POSITIVE TOPLINE RESULTS FROM ITS PHASE 2A RIVER TRIAL OF HADUVIO FOR TREATMENT OF PATIENTS WITH RCC (N=66)
TREVI THERAPEUTICS: PATIENT REPORTED & OTHER SECONDARY OUTCOMES WERE STATISTICALLY SIGNIFICANT & CONSISTENT WITH PRIMARY ENDPOINT
Source text: ID:nPn7xKPQHa
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。